IL128652A0 - N6 heterocyclic substituted adenosine derivatives - Google Patents

N6 heterocyclic substituted adenosine derivatives

Info

Publication number
IL128652A0
IL128652A0 IL12865297A IL12865297A IL128652A0 IL 128652 A0 IL128652 A0 IL 128652A0 IL 12865297 A IL12865297 A IL 12865297A IL 12865297 A IL12865297 A IL 12865297A IL 128652 A0 IL128652 A0 IL 128652A0
Authority
IL
Israel
Prior art keywords
heterocyclic substituted
adenosine derivatives
substituted adenosine
sub
substituted
Prior art date
Application number
IL12865297A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL128652A0 publication Critical patent/IL128652A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12865297A 1996-08-27 1997-08-20 N6 heterocyclic substituted adenosine derivatives IL128652A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08702234 US5789416B1 (en) 1996-08-27 1996-08-27 N6 mono heterocyclic substituted adenosine derivatives
PCT/US1997/014724 WO1998008855A2 (en) 1996-08-27 1997-08-20 N6 heterocyclic substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
IL128652A0 true IL128652A0 (en) 2000-01-31

Family

ID=24820367

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12865297A IL128652A0 (en) 1996-08-27 1997-08-20 N6 heterocyclic substituted adenosine derivatives
IL128652A IL128652A (en) 1996-08-27 1999-02-22 History of adenosine substituted N6 heterocyclic and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL128652A IL128652A (en) 1996-08-27 1999-02-22 History of adenosine substituted N6 heterocyclic and pharmaceutical preparations containing them

Country Status (24)

Country Link
US (1) US5789416B1 (pl)
EP (3) EP1081155A3 (pl)
JP (1) JP3157842B2 (pl)
KR (1) KR100331775B1 (pl)
CN (1) CN100363377C (pl)
AT (2) ATE202361T1 (pl)
AU (1) AU726597B2 (pl)
BR (1) BR9711444A (pl)
CA (1) CA2264155C (pl)
CZ (1) CZ296855B6 (pl)
DE (2) DE69719816T2 (pl)
DK (2) DK0920438T3 (pl)
ES (2) ES2189330T3 (pl)
GE (1) GEP20012419B (pl)
GR (1) GR3036332T3 (pl)
HU (1) HU226057B1 (pl)
IL (2) IL128652A0 (pl)
NO (3) NO312679B1 (pl)
NZ (3) NZ334095A (pl)
PL (1) PL187635B1 (pl)
PT (1) PT920438E (pl)
TR (2) TR199900377T2 (pl)
UA (1) UA62936C2 (pl)
WO (1) WO1998008855A2 (pl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
CA2373279A1 (en) * 1999-05-25 2000-12-14 The Penn State Research Foundation Dna methyltransferase inhibitors
EP1420021A1 (en) * 1999-05-25 2004-05-19 The Penn State Research Foundation DNA Methyltransferase inhibitors
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
CN1482913A (zh) * 2000-09-08 2004-03-17 CV���ƹ�˾ 作为抗心律失常药的嘌呤核苷
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20050227933A1 (en) * 2001-11-29 2005-10-13 Benkovic Stephen J Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
JP4138662B2 (ja) * 2002-01-10 2008-08-27 ザ・ペンシルバニア・ステイト・リサーチ・フアウンデイシヨン アルキルジアリールボリネートおよび錯化ジアリールボロン酸を調製するための方法。
NZ534801A (en) 2002-02-19 2006-04-28 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
CN1646142A (zh) * 2002-04-18 2005-07-27 Cv医药有限公司 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
JP2006502974A (ja) 2002-05-17 2006-01-26 ニューロジェン コーポレイション 置換環縮合イミダゾール誘導体：ｇａｂａａ受容体リガンド
NZ541651A (en) * 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
AU2004238217A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US6881851B1 (en) * 2004-04-21 2005-04-19 Eastman Chemical Company Preparation of tetrahydro-3-furoic acid
PL1758596T3 (pl) * 2004-05-26 2011-01-31 Inotek Pharmaceuticals Corp Pochodne purynowe jako agoniści receptora adenozynowgo A1, oraz sposoby ich zastosowania
CA2581132A1 (en) * 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Purine 5'-carboxamide derivatives and their use as adenosine receptor agonists
CN100451010C (zh) * 2004-12-21 2009-01-14 厦门大学 一种合成(r)-3-氨基四氢呋喃的方法
WO2006125190A1 (en) * 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
CN100344768C (zh) * 2005-11-24 2007-10-24 东华大学 一种3－(s)－氨基四氢呋喃的酶法合成方法
KR20080072721A (ko) * 2005-11-30 2008-08-06 이노텍 파마슈티컬스 코포레이션 퓨린 유도체 및 그의 사용 방법
CA2715289C (en) 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
CN102405286A (zh) 2008-09-22 2012-04-04 阿克赛医药公司 减小大小的自递送RNAi化合物
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
PH12012501320A1 (en) 2010-01-11 2013-01-21 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
KR101852210B1 (ko) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
BR112012023749A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
HRP20171204T1 (hr) 2012-01-26 2017-10-06 Inotek Pharmaceuticals Corporation Anhidridni polimorfi od [(2r,3s,4r,5r)-5-(6-(ciklopentilamino)-9h-purin- 9-il)-3,4-dihidroksitetrahidrofuran-2-il)]metil-nitrata i postupci njihove proizvodnje
KR20150139501A (ko) 2013-03-15 2015-12-11 이노텍 파마슈티컬스 코포레이션 안과용 제형
WO2015084897A2 (en) 2013-12-02 2015-06-11 Mirimmune, Llc Immunotherapy of cancer
US20160304875A1 (en) 2013-12-04 2016-10-20 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
CA2947619A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
JP6836987B2 (ja) 2014-09-05 2021-03-03 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． Ｔｙｒまたはｍｍｐ１を標的とする核酸を用いて老化および皮膚障害を処置するための方法
JP6983752B2 (ja) 2015-07-06 2021-12-17 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. スーパーオキシドディスムターゼ１（ｓｏｄ１）を標的とする核酸分子
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CA3002744A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
CN105218490B (zh) * 2015-11-10 2017-05-03 山东川成医药股份有限公司 一种（r）‑3‑氨基四氢呋喃的制备方法
EP3612152A4 (en) 2017-04-19 2021-02-17 Phio Pharmaceuticals Corp. TOPICAL ADMINISTRATION OF NUCLEIC ACID COMPOUNDS
US20230002766A1 (en) 2019-11-08 2023-01-05 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
EP4085136A1 (en) 2019-12-31 2022-11-09 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
WO2023015265A2 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) * 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
CA1255297A (en) * 1984-10-26 1989-06-06 Bharat Trivedi N.sup.6-benzopyrano and benzothiopyrano adenosines
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
AU626983B2 (en) * 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) * 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer

Also Published As

Publication number Publication date
DK0992510T3 (da) 2003-07-07
GEP20012419B (en) 2001-04-25
DE69719816T2 (de) 2003-12-18
HUP0001640A3 (en) 2002-04-29
US5789416B1 (en) 1999-10-05
JP2000501426A (ja) 2000-02-08
NO312679B1 (no) 2002-06-17
IL128652A (en) 2008-06-05
BR9711444A (pt) 2000-01-18
CA2264155C (en) 2003-11-18
JP3157842B2 (ja) 2001-04-16
CZ296855B6 (cs) 2006-07-12
TR199900377T2 (xx) 1999-05-21
CN1234803A (zh) 1999-11-10
EP0920438A2 (en) 1999-06-09
KR100331775B1 (ko) 2002-04-09
TR200202287T2 (tr) 2003-01-21
ATE202361T1 (de) 2001-07-15
CA2264155A1 (en) 1998-03-05
NZ505428A (en) 2005-03-24
NO20020758L (no) 1999-02-19
KR20000035867A (ko) 2000-06-26
ATE234323T1 (de) 2003-03-15
DE69705312T2 (de) 2001-10-11
NO990787L (no) 1999-02-19
EP1081155A2 (en) 2001-03-07
ES2189330T3 (es) 2003-07-01
NO322459B1 (no) 2006-10-09
PL331853A1 (en) 1999-08-16
DK0920438T3 (da) 2001-09-10
NO990787D0 (no) 1999-02-19
EP1081155A3 (en) 2003-05-02
EP0992510B1 (en) 2003-03-12
AU726597B2 (en) 2000-11-16
WO1998008855A2 (en) 1998-03-05
CZ61499A3 (cs) 1999-10-13
EP0992510A1 (en) 2000-04-12
PT920438E (pt) 2001-10-30
NO20020759D0 (no) 2002-02-15
HK1020967A1 (en) 2000-05-26
NO20020758D0 (no) 2002-02-15
HUP0001640A2 (hu) 2001-05-28
NZ512242A (en) 2004-01-30
DE69705312D1 (de) 2001-07-26
HU226057B1 (en) 2008-04-28
GR3036332T3 (en) 2001-11-30
EP0920438B1 (en) 2001-06-20
ES2157593T3 (es) 2001-08-16
NO20020759L (no) 1999-02-19
DE69719816D1 (de) 2003-04-17
AU4080997A (en) 1998-03-19
WO1998008855A3 (en) 1998-09-03
PL187635B1 (pl) 2004-08-31
CN100363377C (zh) 2008-01-23
UA62936C2 (en) 2004-01-15
US5789416A (en) 1998-08-04
NZ334095A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
US5789416B1 (en) N6 mono heterocyclic substituted adenosine derivatives
AU2720199A (en) Five-membered, benzo-condensed heterocycles used as antithrombotic agents
AU2965889A (en) 3 (3-indoyl) pyrrole-2,5-dione derivatives
AP9901572A0 (en) 2-(Purin-9 yl)-tetrahydrofur-n-3,4-diol derivatives
ZA977687B (en) Substituted 6,5-hetero-bicyclic derivatives
IL128049A0 (en) Substituted 6,6-hetero-bicyclic derivatives
EP1066278A4 (en) ANOREXIGENAL AGENTS BASED ON IMIDAZOLONES: HETEROARYL DERIVATIVES III
AU2055201A (en) N6 heterocyclic 5' modified adenosine derivatives
IL128701A0 (en) 1,2,3,4-Tetrahydro-benzofuro (3,2-c)pyridine derivatives
ATE250607T1 (de) 5h pyrrolo(2,1-c)(1,4)benzodiazepin-3- carboxamidderivate
AU4493496A (en) Substituted 1,4-piperazine-heteroaryl derivatives as 5-ht1d receptor agonists
AU6994396A (en) Substituted indolylpropyl-piperazine derivatives as 5-ht1dalpha agonists
AU6791790A (en) 5-(2-methyl-4,4,4-trifluorobutyl-carbamoyl)indole derivatives
CA2375040A1 (en) Orally active a1 adenosine receptor agonists
ZA962753B (en) 1,3-Dihydro-2H-imidazol-2-one derivatives.
IL139872A0 (en) Derivatives of 3-(2-oxo-[1,3'] bipyrrolidinyl-3-ylidenemethyl) cephems
ZA964621B (en) 2-substituted benzimidazole derivatives.
AU4930696A (en) Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists
AU7578396A (en) Substituted tetrahydropyridine derivatives acting on 5-ht receptors
ZA964622B (en) 2-substituted benzimidazole derivatives.
AU1513597A (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
ZA964692B (en) Benzimidazole derivatives.
ZA966323B (en) Camptothecin derivatives.
PL322917A1 (en) Method of obtaining novel benzyl derivatives with the 1,2,4-triazolyn-5-one system

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted